DUBLIN, Jan 23, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the
"Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025"
report to their offering.
The author estimates that drug sales for schizophrenia in the
5EU reached $806.5m in 2015.
Schizophrenia is a heterogeneous behavioral and cognitive
syndrome involving chronic or recurrent psychosis. The disorder is
characterized by several symptom domains including positive
symptoms (such as hallucinations or delusions and disorganized
speech), negative symptoms (such as a flat affect and poverty of
speech), and cognitive deficits (including attention, memory, and
executive functions). A multitude of antipsychotic products are
currently available for the pharmacological management of
schizophrenia, many of which are already available as inexpensive
generics.
As with the US market, a number of brands available in the 5EU
are expected to face generic erosion following patent expiry during
the forecast period.
The patents protecting Janssen's Invega, Invega Sustenna (known
as Xeplion within the 5EU), and Risperdal Consta; AstraZeneca's
Seroquel; Eli Lilly's Zyprexa (known as Zypadhera); and Allergan's
Vraylar (marketed by Gedeon Richter
in the 5EU) are all due to expire throughout the forecast period,
leaving the 5EU to become widely genericized and limiting sales
growth in these markets.
Scope
- Overview of Schizophrenia including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as
an overview on the competitive landscape.
- Detailed information on the key drugs in the 5EU including
product description, safety and efficacy profiles as well as a SWOT
analysis.
- Sales forecast for the top drugs in the 5EU from
2015-2025.
- Analysis of the impact of key events as well the drivers and
restraints affecting the 5EU Schizophrenia market.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
- Treatment Initiation
- Maintenance Treatment
- Treatment of Breakthrough Episodes
- Long-Acting Injectables
- Treatment-Resistance
- Acute Agitation
- Adjunctive Psychotherapy
5 Competitive Assessment
- Abilify (aripiprazole)
- Aristada (aripiprazole lauroxil)
- Clozapine (widely genericized)
- Fanapt (iloperidone)
- Geodon (ziprasidone)
- Invega (paliperidone)
- Latuda (lurasidone)
- Lonasen (blonanserin)
- Rexulti (brexpiprazole)
- Risperdal (risperidone)
- Saphris (asenapine)
- Seroquel (quetiapine)
- Vraylar (cariprazine)
- Zyprexa (olanzapine)
5.3 Product Profiles - Typical Antipsychotics
- Typical Antipsychotics
- Adasuve (Staccato loxapine)
5.4 Other Therapeutic Classes
6 Unmet Needs and Opportunities
- Development of Cognitive-Enhancing Drugs
- Development of Drugs to Treat Negative Symptoms
- Improved Treatment Options for Treatment-Resistant
Patients
- Development of Drugs with Enhanced Safety Profiles
- Development of Drugs to Increase Compliance
7 Pipeline Assessment
- ALKS-3831
- ITI-007
- Lu AF35700
- MIN-101
- Risperidone implant
- Risperidone ISM
- RBP-7000
- AVN-211
- NaBen
- Other Drugs in Development
8 Market Outlook
9 Appendix
For more information about this report visit
http://www.researchandmarkets.com/research/n893vh/schizophrenia
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716